ClinicalTrials.Veeva

Menu
C

Clinical Research Partners, LLC | Forest Avenue, Richmond, VA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
Linaclotide
MK-7264
Lasmiditan
Upadacitinib
Dupilumab
Gefapixant
Telapristone Acetate
Mirikizumab
Proellex®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 75 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in...

Enrolling
Coeliac Disease
Celiac Disease
Dietary Supplement: SIGE
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix®
Biological: Influsplit®

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

The purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1 and Coh...

Active, not recruiting
Respiratory Syncytial Virus
Biological: mRNA-1345
Biological: Placebo

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participant...

Active, not recruiting
Celiac Disease
Drug: TAK-062 Placebo
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Enrolling
SARS-CoV-2
Biological: mRNA-1273.815
Biological: mRNA-1273.214

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease...

Enrolling
Celiac Disease
Drug: TAK-101
Dietary Supplement: Gluten

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45...

Active, not recruiting
Papillomavirus Infections
Biological: 9vHPV Vaccine
Other: Placebo (Saline for Injection)

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...

Active, not recruiting
COVID-19
Biological: NVX-CoV2601 (5μg)
Biological: NVX-CoV2601 (35μg)
Locations recently updated

This study is to understand if the study vaccine (called VLA15) is safe in healthy children.We are looking for children who:* are healthy* are age 5...

Active, not recruiting
Lyme Disease
Other: Normal Saline
Biological: VLA15
Locations recently updated

The purpose of this study is to select a dose of CD388 that is effective in preventing symptomatic laboratory-confirmed influenza infections, as comp...

Enrolling
Influenza
Combination Product: CD388 Injection
Combination Product: Placebo

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting
COVID-19
Other: Placebo
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)

The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2...

Active, not recruiting
SARS-CoV-2
Biological: mRNA-1273.214
Other: Placebo

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

Enrolling
Atopic Dermatitis
Drug: ruxolitinib cream

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety o...

Enrolling
Hyperuricemia
Gout Flare
Drug: Placebo
Drug: Tigulixostat

Trial sponsors

Moderna logo
AbbVie logo
Incyte logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
Lilly logo
Boehringer Ingelheim logo
Ironwood Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems